KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies

Colorectal cancer (CRC) is a life-threatening disease with high prevalence and mortality worldwide. The KRAS oncogene is mutated in approximately 40% of CRCs. While antibody based EGFR inhibitors (cetuximab and panitumumab) represent a major treatment strategy for advanced KRAS wild type (KRAS-WT) C...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Qing, Dunne, Philip D., O’Reilly, Paul G., Li, Gerald, Bjourson, Anthony J., McArt, Darragh G., Hamilton, Peter W., Zhang, Shu-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356876/
https://www.ncbi.nlm.nih.gov/pubmed/27965461
http://dx.doi.org/10.18632/oncotarget.13884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356876/
https://www.ncbi.nlm.nih.gov/pubmed/27965461
http://dx.doi.org/10.18632/oncotarget.13884

Ejemplares similares